世界のウイルス性呼吸器感染症治療薬市場2020-2030:産業分析、規模、シェア、成長、動向、予測

Transparency Market Researchが発行した調査報告書(TMR21MC036)
◆英語タイトル:Respiratory Virus Infection Drugs Market (Drug Type: Antibiotics, Non-Steroidal Anti-Inflammatory Drugs [NSAIDS], Cough Suppressants, Nasal Decongestants, and Others; Infection Type: Respiratory Syncytial Virus [RSV] Infection, Influenza Virus Infection, Parainfluenza Virus Infection, Adenovirus Infection, Rhinovirus Infection, and Others; Route of Administration: Oral and Parenteral; Mode of Purchase: Prescription-based Drugs and Over-the-counter Drugs; and Distribution Channel: Hospital Pharmacies, Drug Stores, Retail Pharmacies, Clinics, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030
◆商品コード:TMR21MC036
◆発行会社(リサーチ会社):Transparency Market Research
◆発行日:2021年1月4日
◆ページ数:238
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD5,795 ⇒換算¥625,860見積依頼/購入/質問フォーム
Site Licence(同一拠点内共有可)USD8,795 ⇒換算¥949,860見積依頼/購入/質問フォーム
Enterprisewide Licence(複数拠点内共有可)USD11,795 ⇒換算¥1,273,860見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTransparency Market Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Transparency Market Research社の概要及び新刊レポートはこちらでご確認いただけます。

Transparency Market Research社の本調査資料では、世界のウイルス性呼吸器感染症治療薬市場を広く調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、薬剤種類別(抗生物質、非ステロイド性抗炎症薬(NSAIDS)、咳抑制剤、鼻充血除去薬、その他)分析、感染タイプ別分析、投与経路別分析、購入方法別分析、流通チャネル別分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)分析、競争状況など、以下の構成でまとめております。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場概要
・キーインサイト
・ウイルス性呼吸器感染症治療薬の世界市場規模:薬剤種類別(抗生物質、非ステロイド性抗炎症薬(NSAIDS)、咳抑制剤、鼻充血除去薬、その他)
・ウイルス性呼吸器感染症治療薬の世界市場規模:感染タイプ別
・ウイルス性呼吸器感染症治療薬の世界市場規模:投与経路別
・ウイルス性呼吸器感染症治療薬の世界市場規模:購入方法別
・ウイルス性呼吸器感染症治療薬の世界市場規模:流通チャネル別
・ウイルス性呼吸器感染症治療薬の世界市場規模:地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)
・競争状況
【レポートの概要】

Respiratory Virus Infection Drugs Market – Scope of the Report

TMR’s report on the global respiratory virus infection drugs market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2020 to 2030. The report provides revenue of the global respiratory virus infection drugs market for the period 2018–2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global respiratory virus infection drugs market during the forecast period.

The report has been prepared after primary and secondary researches. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global respiratory virus infection drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various phenomenon in the global respiratory virus infection drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global respiratory virus infection drugs market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global respiratory virus infection drugs market.

The report delves into the competition landscape of the global respiratory virus infection drugs market. Key players operating in the global respiratory virus infection drugs market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global respiratory virus infection drugs market that have been profiled in this report.

Key Questions Answered in Respiratory Virus Infection Drugs Market Report

What is the scope of growth for product companies in the global respiratory virus infection drugs market?
What will be the Y-o-Y growth of the global respiratory virus infection drugs market between 2020 and 2030?
What is the influence of changing trends in technologies on the global respiratory virus infection drugs market?
Will North America continue to be the most profitable market for respiratory virus infection drugs?
Which factors are anticipated to hamper the global respiratory virus infection drugs market during the forecast period?
Which are the leading companies in the global respiratory virus infection drugs market?
Research Methodology

A unique methodology has been utilized by TMR to conduct comprehensive research on the growth of the global respiratory virus infection drugs market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary research sources referred to by analysts during the production of the global respiratory virus infection drugs market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the respiratory virus infection drugs market as primary methods.

These primary research respondents have provided exclusive information during interviews, which serves as a validation from the respiratory virus infection drugs market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global respiratory virus infection drugs market with accuracy. The study also uses the top-down approach to assess the revenues of each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global respiratory virus infection drugs more reliably and accurately.

【レポートの目次】

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Respiratory Virus Infection Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, 2018–2030
5. Key Insights
5.1. Healthcare Industry Overview
5.2. Pipeline Analysis (asthma and COPD)
5.3. Regulatory Scenario
5.4. Disease Prevalence Rate in Key Countries
5.5. Key Market Events
5.6. COVID-19 Pandemic Impact on Industry
6. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Type, 2018–2030
6.3.1. Antibiotics
6.3.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
6.3.3. Cough Suppressants
6.3.4. Nasal Decongestants
6.3.5. Others
6.4. Market Attractiveness Analysis, by Drug Type
7. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Infection Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Infection Type, 2018–2030
7.3.1. Respiratory Syncytial Virus (RSV) Infection
7.3.2. Influenza Virus Infection
7.3.3. Parainfluenza Virus Infection
7.3.4. Adenovirus Infection
7.3.5. Rhinovirus Infection
7.3.6. Others
7.4. Market Attractiveness Analysis, by Infection Type
8. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Route of Administration, 2018–2030
8.3.1. Oral
8.3.2. Parenteral
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Mode of Purchase
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Mode of Purchase, 2018–2030
9.3.1. Prescription-based Drugs
9.3.2. Over-the-Counter Drugs
9.4. Market Attractiveness Analysis, by Mode of Purchase
10. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Distribution Channel
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast, by Distribution Channel, 2018–2030
10.3.1. Hospital Pharmacies
10.3.2. Drug Stores
10.3.3. Retail Pharmacies
10.3.4. Clinics
10.3.5. Others
10.4. Market Attractiveness Analysis, by Distribution Channel
11. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness Analysis, by Country/Region
12. North America Respiratory Virus Infection Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Type, 2018–2030
12.2.1. Antibiotics
12.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
12.2.3. Cough Suppressants
12.2.4. Nasal Decongestants
12.2.5. Others
12.3. Market Value Forecast, by Infection Type, 2018–2030
12.3.1. Respiratory syncytial viruses (RSV) Infection
12.3.2. Influenza Virus Infection
12.3.3. Parainfluenza Virus Infection
12.3.4. Adenovirus Infection
12.3.5. Rhinovirus Infection
12.3.6. Others
12.4. Market Value Forecast, by Route of Administration, 2018–2030
12.4.1. Oral
12.4.2. Parenteral
12.5. Market Value Forecast, by Mode of Purchase, 2018–2030
12.5.1. Prescription-based Drugs
12.5.2. Over-the-Counter Drugs
12.6. Market Value Forecast, by Distribution Channel, 2018–2030
12.6.1. Hospital Pharmacies
12.6.2. Drug Stores
12.6.3. Retail Pharmacies
12.6.4. Clinics
12.6.5. Others
12.7. Market Value Forecast, by Country, 2018–2030
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Drug Type
12.8.2. By Infection Type
12.8.3. By Route Of Administration
12.8.4. By Mode of Purchase
12.8.5. By Distribution Channel
12.8.6. By Country
13. Europe Respiratory Virus Infection Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Type, 2018–2030
13.2.1. Antibiotics
13.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
13.2.3. Cough Suppressants
13.2.4. Nasal Decongestants
13.2.5. Others
13.3. Market Value Forecast, by Infection Type, 2018–2030
13.3.1. Respiratory Syncytial Virus (RSV) Infection
13.3.2. Influenza Virus Infection
13.3.3. Parainfluenza Virus Infection
13.3.4. Adenovirus Infection
13.3.5. Rhinovirus Infection
13.3.6. Others
13.4. Market Value Forecast, by Route of Administration, 2018–2030
13.4.1. Oral
13.4.2. Parenteral
13.5. Market Value Forecast, by Mode of Purchase, 2018–2030
13.5.1. Prescription-based Drugs
13.5.2. Over-the-Counter Drugs
13.6. Market Value Forecast, by Distribution Channel, 2018–2030
13.6.1. Hospital Pharmacies
13.6.2. Drug Stores
13.6.3. Retail Pharmacies
13.6.4. Clinics
13.6.5. Others
13.7. Market Value Forecast, by Country/Sub-region, 2018–2030
13.7.1. Germany
13.7.2. U.K.
13.7.3. France
13.7.4. Spain
13.7.5. Italy
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Drug Type
13.8.2. By Infection Type
13.8.3. By Route Of Administration
13.8.4. By Mode of Purchase
13.8.5. By Distribution Channel
13.8.6. By Country/Sub-region
14. Asia Pacific Respiratory Virus Infection Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Type, 2018–2030
14.2.1. Antibiotics
14.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
14.2.3. Cough Suppressants
14.2.4. Nasal Decongestants
14.2.5. Others
14.3. Market Value Forecast, by Infection Type, 2018–2030
14.3.1. Respiratory Syncytial Virus (RSV) Infection
14.3.2. Influenza Virus Infection
14.3.3. Parainfluenza Virus Infection
14.3.4. Adenovirus Infection
14.3.5. Rhinovirus Infection
14.3.6. Others
14.4. Market Value Forecast, by Route Of Administration, 2018–2030
14.4.1. Oral
14.4.2. Parenteral
14.5. Market Value Forecast, by Mode of Purchase, 2018–2030
14.5.1. Prescription-based Drugs
14.5.2. Over-the-Counter Drugs
14.6. Market Value Forecast, by Distribution Channel, 2018–2030
14.6.1. Hospital Pharmacies
14.6.2. Drug Stores
14.6.3. Retail Pharmacies
14.6.4. Clinics
14.6.5. Others
14.7. Market Value Forecast, by Country/Sub-region, 2018–2030
14.7.1. China
14.7.2. Japan
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Drug Type
14.8.2. By Infection Type
14.8.3. By Route of Administration
14.8.4. By Mode of Purchase
14.8.5. By Distribution Channel
14.8.6. By Country/Sub-region
15. Latin America Respiratory Virus Infection Drugs Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Drug Type, 2018–2030
15.2.1. Antibiotics
15.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
15.2.3. Cough Suppressants
15.2.4. Nasal Decongestants
15.2.5. Others
15.3. Market Value Forecast, by Infection Type, 2018–2030
15.3.1. Respiratory Syncytial Virus (RSV) Infection
15.3.2. Influenza Virus Infection
15.3.3. Parainfluenza Virus Infection
15.3.4. Adenovirus Infection
15.3.5. Rhinovirus Infection
15.3.6. Others
15.4. Market Value Forecast, by Route of Administration, 2018–2030
15.4.1. Oral
15.4.2. Parenteral
15.5. Market Value Forecast, by Mode of Purchase, 2018–2030
15.5.1. Prescription-based Drugs
15.5.2. Over-the-Counter Drugs
15.6. Market Value Forecast, by Distribution Channel, 2018–2030
15.6.1. Hospital Pharmacies
15.6.2. Drug Stores
15.6.3. Retail Pharmacies
15.6.4. Clinics
15.6.5. Others
15.7. Market Value Forecast, by Country/Sub-region, 2018–2030
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Drug Type
15.8.2. By Infection Type
15.8.3. By Route of Administration
15.8.4. By Mode of Purchase
15.8.5. By Distribution Channel
15.8.6. By Country/Sub-region
16. Middle East & Africa Respiratory Virus Infection Drugs Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Drug Type, 2018–2030
16.2.1. Antibiotics
16.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
16.2.3. Cough Suppressants
16.2.4. Nasal Decongestants
16.2.5. Others
16.3. Market Value Forecast, by Infection Type, 2018–2030
16.3.1. Respiratory Syncytial Virus (RSV) Infection
16.3.2. Influenza Virus Infection
16.3.3. Parainfluenza Virus Infection
16.3.4. Adenovirus Infection
16.3.5. Rhinovirus Infection
16.3.6. Others
16.4. Market Value Forecast, by Route of Administration, 2018–2030
16.4.1. Oral
16.4.2. Parenteral
16.5. Market Value Forecast, by Mode of Purchase, 2018–2030
16.5.1. Prescription-based Drugs
16.5.2. Over-the-Counter Drugs
16.6. Market Value Forecast, by Distribution Channel, 2018–2030
16.6.1. Hospital Pharmacies
16.6.2. Drug Stores
16.6.3. Retail Pharmacies
16.6.4. Clinics
16.6.5. Others
16.7. Market Value Forecast, by Country/Sub-region, 2018–2030
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Drug Type
16.8.2. By Infection Type
16.8.3. By Route of Administration
16.8.4. By Mode of Purchase
16.8.5. By Distribution Channel
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player – Competition Matrix (by tier and size of companies)
17.2. Market Share Analysis/Ranking, by Company, 2019
17.3. Company Profiles
17.3.1. GlaxoSmithKline plc
17.3.1.1. Company Overview
17.3.1.2. Company Financials
17.3.1.3. Growth Strategies
17.3.1.4. SWOT Analysis
17.3.2. Merck & Co., Inc.
17.3.2.1. Company Overview
17.3.2.2. Company Financials
17.3.2.3. Growth Strategies
17.3.2.4. SWOT Analysis
17.3.3. AstraZeneca
17.3.3.1. Company Overview
17.3.3.2. Company Financials
17.3.3.3. Growth Strategies
17.3.3.4. SWOT Analysis
17.3.4. Boehringer Ingelheim International GmbH
17.3.4.1. Company Overview
17.3.4.2. Company Financials
17.3.4.3. Growth Strategies
17.3.4.4. SWOT Analysis
17.3.5. F. Hoffmann-La Roche Ltd.
17.3.5.1. Company Overview
17.3.5.2. Company Financials
17.3.5.3. Growth Strategies
17.3.5.4. SWOT Analysis
17.3.6. Teva Pharmaceutical Industries Ltd.
17.3.6.1. Company Overview
17.3.6.2. Company Financials
17.3.6.3. Growth Strategies
17.3.6.4. SWOT Analysis
17.3.7. Sanofi
17.3.7.1. Company Overview
17.3.7.2. Company Financials
17.3.7.3. Growth Strategies
17.3.7.4. SWOT Analysis
17.3.8. Cipla, Inc.
17.3.8.1. Company Overview
17.3.8.2. Company Financials
17.3.8.3. Growth Strategies
17.3.8.4. SWOT Analysis
17.3.9. CHIESI Farmaceutici S.p.A.
17.3.9.1. Company Overview
17.3.9.2. Company Financials
17.3.9.3. Growth Strategies
17.3.9.4. SWOT Analysis
17.3.10. Orion Corporation
17.3.10.1. Company Overview
17.3.10.2. Growth Strategies
17.3.10.3. SWOT Analysis

List of Tables

Table 01: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030

Table 02: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Infection Type, 2018–2030

Table 03: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 04: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030

Table 05: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 06: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Region, 2018–2030

Table 07: North America Respiratory Virus Infection Drugs Market Revenue (US$ Mn) Forecast, by Country, 2018–2030

Table 08: North America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030

Table 09: North America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Infection Type, 2018–2030

Table 10: North America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 11: North America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Mode of Purchase, 2018–2030

Table 12: North America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 13: Europe Respiratory Virus Infection Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 14: Europe Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030

Table 15: Europe Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Infection Type, 2018–2030

Table 16: Europe Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 17: Europe Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Mode of Purchase, 2018–2030

Table 18: Europe Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 19: Asia Pacific Respiratory Virus Infection Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 20: Asia Pacific Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030

Table 21: Asia Pacific Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Infection Type, 2018–2030

Table 22: Asia Pacific Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 23: Asia Pacific Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Mode of Purchase, 2018–2030

Table 24: Asia Pacific Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 25: Latin America Respiratory Virus Infection Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 26: Latin America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030

Table 27: Latin America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Infection Type, 2018–2030

Table 28: Latin America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 29: Latin America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Mode of Purchase, 2018–2030

Table 30: Latin America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 31: Middle East & Africa Respiratory Virus Infection Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 32: Middle East & Africa Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030

Table 33: Middle East & Africa Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Infection Type, 2018–2030

Table 34: Middle East & Africa Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 35: Middle East & Africa Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Mode of Purchase, 2018–2030

Table 36: Middle East & Africa Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

List of Figures

Figure 01: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, 2018–2030

Figure 02: Global Respiratory Virus Infection Drugs Market Value Share, by Drug Type, 2019

Figure 03: Global Respiratory Virus Infection Drugs Market Value Share, by Infection Type, 2019

Figure 04: Global Respiratory Virus Infection Drugs Market Value Share, by Route of Administration, 2019

Figure 05: Global Respiratory Virus Infection Drugs Market Value Share, by Mode of Purchase, 2019

Figure 06: Global Respiratory Virus Infection Drugs Market Value Share, by Distribution Channel, 2019

Figure 07: Global Respiratory Virus Infection Drugs Market Value Share, by Region, 2019

Figure 08: Global Respiratory Virus Infection Drugs Market Value Share Analysis, by Drug Type, 2019 and 2030

Figure 09: Global Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Drug Type, 2020–2030

Figure 10: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Antibiotics, 2018–2030

Figure 11: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Non-steroidal Anti-inflammatory Drugs (NSAIDS), 2018–2030

Figure 12: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Cough Suppressants, 2018–2030

Figure 13: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Nasal Decongestants, 2018–2030

Figure 14: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Others, 2018–2030

Figure 15: Global Respiratory Virus Infection Drugs Market Value Share Analysis, by Infection Type, 2019 and 2030

Figure 16: Global Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Infection Type, 2020–2030

Figure 17: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Respiratory Syncytial Virus (RSV) Infection, 2018–2030

Figure 18: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Influenza Virus Infection, 2018–2030

Figure 19: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Parainfluenza Virus Infection, 2018–2030

Figure 20: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Adenovirus Infection, 2018–2030

Figure 21: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Rhinovirus Infection, 2018–2030

Figure 22: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Others, 2018–2030

Figure 23: Global Respiratory Virus Infection Drugs Market Value Share Analysis, by Route of Administration, 2019 and 2030

Figure 24: Global Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 25: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Oral, 2018–2030

Figure 26: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Parenteral, 2018–2030

Figure 27: Global Respiratory Virus Infection Drugs Market Value Share Analysis, by Mode of Purchase, 2019 and 2030

Figure 28: Global Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Mode of Purchase, 2020–2030

Figure 29: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Prescription-based Drugs, 2018–2030

Figure 30: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Over-the-Counter Drugs, 2018–2030

Figure 31: Global Respiratory Virus Infection Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 32: Global Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 33: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Hospital Pharmacies, 2018–2030

Figure 34: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Drug Stores, 2018–2030

Figure 35: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Retail Pharmacies, 2018–2030

Figure 36: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Clinics, 2018–2030

Figure 37: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Others, 2018–2030

Figure 38: Global Respiratory Virus Infection Drugs Market Value Share Analysis, by Region, 2019 and 2030

Figure 39: Global Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Region

Figure 40: North America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 41: North America Respiratory Virus Infection Drugs Market Value Share (%), by Country, 2019 and 2030

Figure 42: North America Respiratory Virus Infection Drugs Market Attractiveness, by Country, 2020–2030

Figure 43: North America Respiratory Virus Infection Drugs Market Value Share (%), by Drug Type, 2019 and 2030

Figure 44: North America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Drug Type, 2020–2030

Figure 45: North America Respiratory Virus Infection Drugs Market Value Share (%), by Infection Type, 2019 and 2030

Figure 46: North America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Infection Type, 2020–2030

Figure 47: North America Respiratory Virus Infection Drugs Market Value Share (%), by Route of Administration, 2019 and 2030

Figure 48: North America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 49: North America Respiratory Virus Infection Drugs Market Value Share (%), by Mode of Purchase, 2019 and 2030

Figure 50: North America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Mode of Purchase, 2020–2030

Figure 51: North America Respiratory Virus Infection Drugs Market Value Share (%), by Distribution Channel, 2019 and 2030

Figure 52: North America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 53: Europe Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 54: Europe Respiratory Virus Infection Drugs Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 55: Europe Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Figure 56: Europe Respiratory Virus Infection Drugs Market Value Share (%), by Drug Type, 2019 and 2030

Figure 57: Europe Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Drug Type, 2020–2030

Figure 58: Europe Respiratory Virus Infection Drugs Market Value Share (%), by Infection Type, 2019 and 2030

Figure 59: Europe Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Infection Type, 2020–2030

Figure 60: Europe Respiratory Virus Infection Drugs Market Value Share (%), by Route of Administration, 2019 and 2030

Figure 61: Europe Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 62: Europe Respiratory Virus Infection Drugs Market Value Share (%), by Mode of Purchase, 2019 and 2030

Figure 63: Europe Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Mode of Purchase, 2020–2030

Figure 64: Europe Respiratory Virus Infection Drugs Market Value Share (%), by Distribution Channel, 2019 and 2030

Figure 65: Europe Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 66: Asia Pacific Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 67: Asia Pacific Respiratory Virus Infection Drugs Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 68: Asia Pacific Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Figure 69: Asia Pacific Respiratory Virus Infection Drugs Market Value Share (%), by Drug Type, 2019 and 2030

Figure 70: Asia Pacific Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Drug Type, 2020–2030

Figure 71: Asia Pacific Respiratory Virus Infection Drugs Market Value Share (%), by Infection Type, 2019 and 2030

Figure 72: Asia Pacific Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Infection Type, 2020–2030

Figure 73: Asia Pacific Respiratory Virus Infection Drugs Market Value Share (%), by Route of Administration, 2019 and 2030

Figure 74: Asia Pacific Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 75: Asia Pacific Respiratory Virus Infection Drugs Market Value Share (%), by Mode of Purchase, 2019 and 2030

Figure 76: Asia Pacific Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Mode of Purchase, 2020–2030

Figure 77: Asia Pacific Respiratory Virus Infection Drugs Market Value Share (%), by Distribution Channel, 2019 and 2030

Figure 78: Asia Pacific Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 79: Latin America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 80: Latin America Respiratory Virus Infection Drugs Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 81: Latin America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Figure 82: Latin America Respiratory Virus Infection Drugs Market Value Share (%), by Drug Type, 2019 and 2030

Figure 83: Latin America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Drug Type, 2020–2030

Figure 84: Latin America Respiratory Virus Infection Drugs Market Value Share (%), by Infection Type, 2019 and 2030

Figure 85: Latin America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Infection Type, 2020–2030

Figure 86: Latin America Respiratory Virus Infection Drugs Market Value Share (%), by Route of Administration, 2019 and 2030

Figure 87: Latin America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 88: Latin America Respiratory Virus Infection Drugs Market Value Share (%), by Mode of Purchase, 2019 and 2030

Figure 89: Latin America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Mode of Purchase, 2020–2030

Figure 90: Latin America Respiratory Virus Infection Drugs Market Value Share (%), by Distribution Channel, 2019 and 2030

Figure 91: Latin America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 92: Middle East & Africa Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 93: Middle East & Africa Respiratory Virus Infection Drugs Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 94: Middle East & Africa Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Figure 95: Middle East & Africa Respiratory Virus Infection Drugs Market Value Share (%), by Drug Type, 2019 and 2030

Figure 96: Middle East & Africa Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Drug Type, 2020–2030

Figure 97: Middle East & Africa Respiratory Virus Infection Drugs Market Value Share (%), by Infection Type, 2019 and 2030

Figure 98: Middle East & Africa Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Infection Type, 2020–2030

Figure 99: Middle East & Africa Respiratory Virus Infection Drugs Market Value Share (%), by Route of Administration, 2019 and 2030

Figure 100: Middle East & Africa Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 101: Middle East & Africa Respiratory Virus Infection Drugs Market Value Share (%), by Mode of Purchase, 2019 and 2030

Figure 102: Middle East & Africa Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Mode of Purchase, 2020–2030

Figure 103: Middle East & Africa Respiratory Virus Infection Drugs Market Value Share (%), by Distribution Channel, 2019 and 2030

Figure 104: Middle East & Africa Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のウイルス性呼吸器感染症治療薬市場2020-2030:産業分析、規模、シェア、成長、動向、予測(Respiratory Virus Infection Drugs Market (Drug Type: Antibiotics, Non-Steroidal Anti-Inflammatory Drugs [NSAIDS], Cough Suppressants, Nasal Decongestants, and Others; Infection Type: Respiratory Syncytial Virus [RSV] Infection, Influenza Virus Infection, Parainfluenza Virus Infection, Adenovirus Infection, Rhinovirus Infection, and Others; Route of Administration: Oral and Parenteral; Mode of Purchase: Prescription-based Drugs and Over-the-counter Drugs; and Distribution Channel: Hospital Pharmacies, Drug Stores, Retail Pharmacies, Clinics, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆